Jazz Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines for rare diseases, including rare epilepsies, cancers, and sleep disorders. Its portfolio includes Xywav (calcium, magnesium, potassium, and sodium oxybates) for narcolepsy and idiopathic hypersomnia, Epidiolex (cannabidiol) for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex, and Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer. Other marketed products include Modeyso (dordaviprone) for diffuse midline glioma, Zepzelca (lurbinectedin) for small cell lung cancer, and Rylaze (asparaginase erwinia chrysanthemi) for acute lymphoblastic leukemia. The company operates globally, with products approved in the United States, the European Union, Great Britain, Canada, and other markets. Epidiolex is marketed as Epidyolex in the EU and Great Britain, while Rylaze is marketed as Enrylaze in the EU. The company focuses on addressing unmet medical needs in patient populations with limited therapeutic options.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage jazzpharma.com
Sector Healthcare IR page investor.jazzpharma.com
Tags
rare diseases, epilepsy, oncology, sleep disorders, narcolepsy, small cell lung cancer, biliary tract cancer, glioma, leukemia, cannabidiol, oxybate therapy, asparaginase, Xywav, Epidiolex, Ziihera, Modeyso, Zepzelca, Rylaze, Epidyolex, Enrylaze, Defitelio, Vyxeos, Xyrem
Press page —

Metrics

Valuation  
Market cap $ 15.164B
Market cap (USD) $ 15.164B
P/E 76.95
PEG —
P/BV 3.62
P/S 3.21
P/OCF 8.96
P/FCF 9.35
Dividend yield —
Turnover / mcap —
Returns  
ROE -8.5%
ROI -3.7%
ROIC -3.3%
Profit margin -8.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 132.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 76
Quality score -11.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 4.268B 4.069B 3.834B 3.659B 3.094B 2.364B 2.162B 1.891B 1.619B 1.488B 1.325B 1.173B 872.423M 585.979M 272.277M 173.781M 128.449M 67.514M 65.303M 44.856M
Net profit -356.148M 560.12M 414.832M -224.06M -329.668M 238.616M 523.367M 447.098M 487.848M 396.831M 329.535M 58.387M 216.312M 288.586M 124.984M 32.778M -6.836M -184.339M -138.826M -59.391M
Free cash flow 1.297B 1.358B 1.068B 1.243B 750.866M 884.644M 736.266M 778.534M 664.137M 582.704M 495.985M 369.418M 273.64M 243.776M 150.317M 58.137M -15.931M -131.971M -84.24M -59.032M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Share price 170 123.15 123 159.31 127.4 165.05 149.28 123.96 134.65 109.03 140.56 163.73 126.56 53.22 37.36 18.38 7.49 8.47 13.39 —
Price performance 12m 0.38 0 -0.23 0.25 -0.23 0.11 0.2 -0.08 0.23 -0.22 -0.14 0.29 1.38 0.42 1.03 1.46 -0.12 -0.37 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 234M 224M 264M 356M 396M 563M 651M 706M 717M 831M
↳ YoY growth +11.7% -4.3% +17.7% +34.9% +11.4% +42.1% +15.6% +8.3% +1.6% +15.9%
↳ 5y CAGR +46.8% +24.3% +16.2% +13.8% +13.6% +19.2% +23.8% +21.7% +15.0% +15.9%
Borrowings, current (USD) 36.1M 40.6M 33.4M 33.4M 246M 31M 31M 605M 31M 1.03B
Borrowings, non-current (USD) 1.99B 1.54B 1.56B 1.57B 1.85B 6.02B 5.69B 5.11B 6.08B 4.33B
Lease liabilities (USD) — — 0.00 164M 154M 109M 93M 83.7M 58.3M 69M
Cash and deposits (USD) 366M 386M 310M 637M 1.06B 591M 881M 1.51B 2.41B 1.39B
Intangible assets (USD) 3.01B 2.98B 2.73B 2.44B 2.2B 7.15B 5.79B 5.42B 4.76B 4.43B
Right-of-use assets (USD) — — 0.00 139M 129M 86.6M 73.3M 65.3M 53.6M 58.9M
Net debt (borrowings + leases - cash) (USD) 1.66B 1.2B 1.29B 1.13B 1.19B 5.57B 4.94B 4.29B 3.75B 4.04B
Cash flow detail
Operating cash flow (USD) 591M 693M 799M 776M 900M 779M 1.27B 1.09B 1.4B 1.36B
Purchases of property, plant and equipment (USD) -7.83M -29M -20.4M -40.1M -15M -27.6M -29M -24M -38.1M -58.8M
Purchases of intangible assets (USD) -150M 0.00 -111M -80.5M -113M -17.9M -25M 0.00 0.00 -109M
Change in receivables (cash effect) (USD) -25.6M 12.3M -40.1M -92.3M -38.6M -92.7M -90.1M -51.9M -21.1M -106M
Change in inventories (cash effect) (USD) -17M -8.67M -18.5M -32.8M -30.5M -48.9M -49.6M -13.4M -45.5M -86M
Change in payables (cash effect) (USD) 361,000 214,000 17M 4.77M -18.9M 57M -11.2M 9.6M -20.1M 39.9M
Share buybacks (cash effect) (USD) -278M -98.8M -524M -301M -147M 0.00 -54,000 -270M -311M -125M
Interest paid (cash effect) (USD) -39.9M -44.6M -42.7M -43M -42.5M -138M -271M -333M -315M -249M
Income taxes paid (cash effect) (USD) -160M -174M -164M -184M -227M -271M -94.7M -178M -115M -122M
Share-based compensation (USD) 98.8M 107M 102M 111M 121M 189M 222M 227M 248M 291M
Operating cash flow before change in receivables (USD) 616M 681M 839M 869M 938M 871M 1.36B 1.14B 1.42B 1.46B
Free cash flow (OCF - PPE - intangibles) (USD) 433M 664M 667M 656M 772M 733M 1.22B 1.07B 1.36B 1.19B
Income detail
Research and development expense (USD) 162M 198M 227M 300M 335M 506M 590M 850M 884M 783M
↳ 5y CAGR +63.0% +57.5% +37.2% +28.6% +19.9% +25.5% +24.4% +30.3% +24.1% +18.5%
Total comprehensive income (USD) 347M 664M 390M 498M 328M -596M -949M 698M 455M 22.9M
Comprehensive income to owners (USD) 347M 664M 390M 498M 328M -596M -949M 698M 455M 22.9M
Reported Feb 28, 2017 Feb 27, 2018 May 7, 2019 Feb 25, 2020 Feb 23, 2021 Mar 1, 2022 Mar 1, 2023 Feb 28, 2024 Feb 26, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 03, 2026

Download PDF

DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:

  • Jefferies London Global Healthcare Conference on Tuesday, November 17, 2026, at 8:00 a.m. ET

  • Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, at 8:00 a.m. ET

  • Citi's 2026 Global Healthcare Conference on Wednesday, December 2, 2026, at 3:00 p.m. ET

Audio webcasts of the fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.

About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

November 02, 2026

Download PDF

Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare brain cancers

For U.S. media and investors only

DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that clinical and preclinical research from its neuro-oncology portfolio will be presented at the upcoming 2026 Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 12-15 in Philadelphia.

Key highlights include:

  • The confirmatory Phase 3 ACTION trial evaluating Modeyso® (dordaviprone), formerly ONC201, continues to advance. In the trial, patients with newly diagnosed H3 K27M-mutant diffuse glioma who have completed standard frontline radiotherapy are randomized 1:1:1 to receive placebo, once-weekly dordaviprone, or twice-weekly dordaviprone on two consecutive days. The primary efficacy endpoint is overall survival.

  • A Phase 2 clinical trial for JZP3507 (formerly ONC206) has been initiated in recurrent meningioma, the most common form of primary central nervous system cancer in adults. JZP3507 is a dual targeted investigational therapy that is an agonist of the mitochondrial protease ClpP and an antagonist of the G protein-coupled receptor DRD2.

  • An oral presentation for JZP3507 will show new preclinical findings characterizing the anti-cancer activity in H3 G34-mutant glioma. JZP3507 demonstrated nanomolar potency in cell lines and patient-derived cells, as well as a ClpP-dependent mechanism underlying its anti-cancer effects.

"The data being presented at SNO demonstrates Jazz's expanding commitment to scientific innovation and our progress to develop new therapies for patients facing rare and highly aggressive brain cancers," said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. "Building on the landmark approval of Modeyso, we are advancing the Phase 3 ACTION trial, with an interim analysis in the first half of 2027, to potentially bring this therapy to patients earlier in the disease course."

Presentations at SNO 2026 include:

| Presentation Title | Authors | Presentation Details |

| ACTION trial update: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma | Arrillaga-Romany I*, Chang JH, Pellerino A, Brazil L, Cappellano A, McBain C, Lombardi G, Cardoso A, Dahlrot RH, Carceller F, Gironés Sarrió R, Pavon-Mengual M, Bhatia A, Allen J, Melemed A, Mayo C, Tarapore R, Wen P, Cloughesy T | **Type:**Poster presentation Location: Exhibit Hall D & E, Second Floor, Pennsylvania Convention Center **Date:**Friday, November 13, 7:30-9:30 p.m. ET **Number:**TIP-11 |

| A phase 2 study to investigate the efficacy and safety of JZP3507 (formerly ONC206) in adults with recurrent grade 2 or 3 meningioma | Ramage S*, Arrillaga-Romany I, Barbaro M, Gatson N, Johnson M, Kurz S, Mendez J, Odia Y, Sharma A, Umemura Y, Wen P, Mayo C, Shonka N | **Type:**Poster presentation Location: Exhibit Hall D & E, Second Floor, Pennsylvania Convention Center **Date:**Friday, November 13, 7:30-9:30 p.m. ET **Number:**TIP-12 |

| Allosteric ClpP agonist ONC206 alters mitochondrial metabolism to elicit anti-cancer efficacy in H3 G34-mutant glioma | Prabhu V*, Lee A, Maranto C, Foster S, Allen J | **Type:**Oral presentation **Date:**Saturday, November 14, 2:30-3:30pm ET Location: 120 ABC, First Floor, Pennsylvania Convention Center **Number:**EXTH-15 |

| EGFR signaling drives mesenchymal cell-state transition and therapeutic vulnerability in H3K27M-mutant Diffuse Midline Glioma | Ji S, Doherty R, Pearson A*, Wink K, Lau B, Murthy B, Mota M, Natarajan S, de la Nava D, Sajjakulnukit P, Adam T, Niculcea M, Vo K, Bavani S, Yadavalli S, Cruz A, Li F, Knowles T, Phillips J, Vo T, Liu I, Kumar P, McThenia S, Mazewski C, Pytel N, Bowers D, Green A, Lyssiotis C, Qin T, Solomon D, Beck A, Nuechterlein N, Agnihotri S, Toll S, Dun M, Venneti S, Mueller S, Nazarian J, Waszak S, Koschmann C | **Type:**Pediatric Oral Abstracts Session I **Date:Saturday,**November 14, 3:45-4:45pm ET **Location:**120 ABC, First Floor, Pennsylvania Convention Center **Number:**CSIG-09 |

| Spatial Architecture of H3 K27M-mutant Diffuse Midline Glioma Reveals Prognostic Niches in Patients from the PNOC022 Clinical Trial | Savary C*, Vo T, Jackson E, Persson M, Dubois O, Douglas A, McEwen H, McLachlan T, Kline C, Franson A, Valvi S, van der Lugt J, Nazarian J, Waszak S, Koschmann C, Gupta N, Mueller S, Dun M | **Type:**CNS Rare Tumor Oral Abstracts Session I **Date:**Friday, November 13, 2:30-3:30pm ET **Location:**119 AB, First Floor, Pennsylvania Convention Center **Number:**BIOM-72 |

| Leveraging the immunomodulatory effects of dordaviprone to induce adaptive immune surveillance in diffuse midline glioma | Persson M*, Savary C, Jackson E, Duchatel R, Vo T, Dubois O, Loughnan O, Findlay I, Douglas A, Bramberger L, de la Nava D, McEwen H, Beitaki T, Mannan A, Jayaraman R, Thomas B, Rodriguez de la Fuente L, Colino-Sanguino Y, Valdes Mora F, Faridi P, Holst J, Mayall J, Kline C, Franson A, Venneti V, Hondermarck H, Horvat J, Pearson A, Ji S, Nazarian J, Hulleman E, Mueller S, Vitanza N, Koschmann C, Alonso M, Carvalheiro T, van der Lugt J, Dun M | Type: Rapid Orals Session VI A Poster Session **Date:**Friday, November 13, 11:30am-12:30pm ET Friday, November 13, 7:30-9:30pm ET Location: Exhibit Hall D & E, Second Floor, Pennsylvania Convention Center **Number:**TMIC-98 |

| Exploiting Tumor Stress and Innate Immunity: ONC201 Enhances NK Cell Therapy for Pediatric Diffuse Midline Gliomas | Cheng D, Zhang P, Basar R, Shanley M, Singh A, Swaminathan J, Shrestha R, Siddaway R, Vadivel AA, Sharma A, Yang Y, Anjier A, Maegawa S, Feng S, Gordon N, Daw N, Gorlick R, Tarapore R, Prabhu V, Allen J, Koul D, Hawkins C, Zaky W, Wintermark M, Rezvani K, Gopalakrishnan V* | **Type:**Poster Session Date: Friday, November 13, 7:30-9:30pm ET **Location:**Exhibit Hall D & E, Second Floor, Pennsylvania Convention Center **Number:**EXTH-26 |

| In vitro and in vivo evaluation of CT-179 in combination with ONC201 and ONC206 in patient-derived models of diffuse midline glioma | Mizoguchi S, Yu J, Kritzer B, Laternser S, Stein G, Kesari S, Packer P, Nazarian J, Yadavilli S* | Type: Poster Session **Date:**Friday, November 13, 7:30-9:30pm ET **Location:**Exhibit Hall D & E, Second Floor, Philadelphia Convention Center **Number:**EXTH-33 |

| * Presenting author |

About Modeyso®(dordaviprone) Modeyso (dordaviprone) is approved by FDA for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.1 Modeyso is an orally administered small molecule given once weekly. Modeyso is a protease activator of the mitochondrial ClpP and also inhibits DRD2. In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1

Modeyso received accelerated approval based on overall response rate and duration of response derived from a pre-specified integrated efficacy analysis of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label clinical studies (ONC006, ONC013, ONC014, ONC016, and ONC018). Full approval for this indication is contingent upon us satisfying post-marketing requirements, including the verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial and other applicable post-marketing commitments. The FDA granted dordaviprone Rare Pediatric Disease designation and Fast-Track designation, and dordaviprone received Orphan Drug Designation in the United States, Europe and Australia. Modeyso was developed by Chimerix prior to its acquisition by Jazz Pharmaceuticals in April 2025.

Modeyso (dordaviprone) is approved in the United States and Japan. It is not approved anywhere else in the world.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS Hypersensitivity MODEYSO can cause severe hypersensitivity reactions.

In the pooled safety population, Grade 3 hypersensitivity reactions occurred in 0.3% of patients receiving MODEYSO. Signs and symptoms of hypersensitivity may include rash, hives, fever, low blood pressure, wheezing, or swelling of the face or throat.

Inform patients about the signs and symptoms of hypersensitivity reactions and instruct them to seek immediate medical attention if symptoms occur.

If clinically significant hypersensitivity or anaphylaxis occur, immediately interrupt MODEYSO and initiate appropriate medical treatment and supportive care. Based on the severity of the adverse reaction, temporarily interrupt or permanently discontinue MODEYSO.

QTc Interval Prolongation MODEYSO causes concentration-dependent QTc interval prolongation, which can increase the risk for ventricular tachyarrhythmias (e.g. torsades de pointes) or sudden death.

In patients who received MODEYSO and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 6% and 1.2% of patients, respectively.

Monitor ECGs and electrolytes prior to initiation and periodically during treatment, as clinically indicated. Increase the frequency of monitoring in patients with congenital long QT syndrome, existing QTc prolongation, a history of ventricular arrhythmias, electrolyte abnormalities, heart failure, or who are taking strong or moderate CYP3A4 inhibitors.

Avoid concomitant use with other agents known to prolong the QT interval. If concomitant use cannot be avoided, increase the frequency of monitoring and separate administration of MODEYSO and QT-prolonging product.

Interrupt or reduce the dose of MODEYSO in patients who develop QT prolongation; permanently discontinue in patients with signs of life-threatening arrhythmias.

Embryo-Fetal Toxicity MODEYSO can cause fetal harm when administered to a pregnant woman.

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with MODEYSO and for 1 month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with MODEYSO and for 1 month after the last dose.

ADVERSE REACTIONS Serious adverse reactions occurred in 33% of the 376 patients who received MODEYSO. Serious adverse reactions in >2% of patients included hydrocephalus (5%), vomiting (4.3%), headache (3.2%), seizure (2.4%), and muscular weakness (2.1%). Fatal adverse reactions occurred in 1% of patients who received MODEYSO, including cardiac arrest (0.5%), intracranial hemorrhage (0.3%), and encephalopathy (0.3%).

The most common adverse reactions (≥20%) reported in clinical trials with MODEYSO were fatigue (34%), headache (32%), vomiting (24%), nausea (24%), and musculoskeletal pain (20%). The most common (≥2%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes (7%), decreased calcium (2.7%), and increased alanine aminotransferase (2.4%).

DRUG INTERACTIONS Strong and Moderate CYP3A4 Inhibitors Avoid concomitant use of MODEYSO with strong and moderate CYP3A4 inhibitors. If concomitant use cannot be avoided, reduce the MODEYSO dose as recommended and monitor for toxicity.

Strong and Moderate CYP3A4 Inducers Avoid concomitant use of strong and moderate CYP3A4 inducers with MODEYSO.

USE IN SPECIFIC POPULATIONS Lactation There are no data on the presence of MODEYSO in human milk because of the potential for serious adverse reactions from MODEYSO in breastfed children, advise women not to breastfeed during treatment with MODEYSO and for 1 week after the last dose.

Pediatric Use The safety and effectiveness of MODEYSO have not been established in patients less than 1 year of age. Dosing has not been established for patients weighing less than 22 pounds (10 kg).

Please refer to the full Prescribing Information, including both Patient Information and Instructions for Use, for complete safety and administration information.

The full U.S. Prescribing Information for MODEYSO is available at:https://pp.jazzpharma.com/pi/modeyso.en.USPI.pdf

About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

November 02, 2026

Download PDF

– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) –

– Company raises full year 2026 total revenue guidance –

– Ziihera® launched in HER2+ 1L mGEA –

– Xywav® revenues grew 12% YoY with 425 net patient adds in 3Q26 –

– Closed Actio acquisition, adding ABS-1230 (JZP6979) to rare epilepsy portfolio –

DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2026 (3Q26).

"Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. "At the same time, we continue to strengthen the drivers of our future growth, with the approval and rapid launch of Ziihera in first-line HER2-positive GEA and the acquisition of Actio, which adds ABS-1230 and deepens our pipeline in rare, refractory epilepsies. Jazz is moving with momentum and urgency to advance practice-changing medicines that deliver meaningful benefit for patients and durable value for shareholders."

Recent Key Highlights

  • Achieved total revenues of $1.2 billion in 3Q26, reflecting 10% year-over-year (YoY) growth.

  • Received U.S. Food and Drug Administration (FDA) approval and rapidly launched Ziihera-based combinations in first-line (1L) gastroesophageal adenocarcinoma (GEA).

  • Presented final analysis from the HERIZON-GEA-01 trial at European Society for Medical Oncology Congress 2026 (ESMO), demonstrating sustained survival benefit at three years. Longer follow-up of Ziihera plus tislelizumab and chemotherapy showed an improved overall survival (OS) hazard ratio of 0.65, further supporting Ziihera-based combinations as standard-of-care.

  • Closed acquisition of Actio Biosciences, Inc. (Actio), adding ABS-1230 (JZP6979) to rare epilepsy portfolio.

  • Generated $1.3 billion in cash from operations in the first nine months of 2026.

  • Raised 2026 total revenue guidance to a range of $4.775 - $4.85 billion.

Business Updates

Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution:

  • Xywav net product sales increased 12% YoY to $483 million in 3Q26.

  • Robust new patient growth drove revenue, with approximately 425 net patient adds in 3Q26. There were approximately 17,550 active patients exiting the quarter, comprised of approximately 11,375 narcolepsy patients and approximately 6,175 idiopathic hypersomnia patients.

  • Continued physician and patient demand for the differentiated benefits of low-sodium Xywav.

Epidiolex/Epidyolex**®** (cannabidiol):

  • Epidiolex/Epidyolex net product sales decreased 2% YoY to $295 million in 3Q26. The 3Q26 growth rate was negatively affected by lower U.S. gross-to-net deductions in 3Q25 and lower levels of inventory build in 3Q26 due to wholesaler buying patterns.

  • The PDUFA target action date for our New Drug Application (NDA) for the oral cannabidiol capsule formulation is April 16, 2027.

Ziihera (zanidatamab-hrii):

  • Ziihera net product sales were $21 million in 3Q26.

  • Ziihera received FDA approval on August 25, 2026, and was launched promptly for the first-line treatment of adult patients with HER2-positive (HER2+) unresectable locally advanced or metastatic GEA.

  • Promising early demand from first full month of 1L GEA launch with ~40% increase in average demand vials per selling day and a threefold increase in new ordering accounts, 80% of which are community based.

  • Positive results from the second and final OS analysis for the HERIZON-GEA-01 trial were presented at ESMO. Mature HERIZON-GEA-01 results showed Ziihera plus chemotherapy delivered statistically significant and clinically meaningful OS benefit. Nearly 40% of patients were alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months.

  • NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) for Gastric Cancer, and Esophageal and Esophagogastric Junction Cancers, were updated to include Ziihera (zanidatamab-hrii) in combination with chemotherapy, with and without Tevimbra® (tislelizumab-jsgr), as a preferred regimen for first-line treatment of adult patients with HER2+ unresectable locally advanced or metastatic GEA.

Modeyso™ (dordaviprone):

  • Modeyso net product sales were $61 million in 3Q26 with approximately 725 patients having received Modeyso from product launch in August 2025 through the end of 3Q26.

  • The company anticipates the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, based on the current pace of event accrual.

Zepzelca® (lurbinectedin):

  • Zepzelca net product sales increased 32% YoY to $104 million in 3Q26, driven by continued uptake of the Zepzelca and atezolizumab combination in the 1L maintenance extensive-stage small-cell lung cancer setting, partially offset by a decline in second-line use.

  • On September 30, 2026, the FDA approved the label supplement removing the second-line indication.

Actio Acquisition:

  • Completed the Actio acquisition in September 2026, adding ABS-1230 (JZP6979) to rare epilepsy portfolio.

  • Potential first-in-class precision therapy for KCNT1-related epilepsy which has demonstrated meaningful seizure reductions in an early clinical proof-of-concept trial in children with KCNT1 epilepsy.

  • Currently being evaluated in the ongoing Phase 1b/2a KYRON trial designed to serve as a registrational study to support an NDA submission in the U.S.

  • Expect to present initial patient data at a medical meeting in 4Q26.

Capital StructureIn the third quarter of 2026, the company completed a private placement of $1.25 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (2032 notes). Concurrent with this transaction, the company repurchased $225 million of its ordinary shares. The company paid for the repurchases with existing cash on hand, and the share repurchases were effected under, and completely exhausted, the company's share repurchase program announced in July 2024. In October 2026, the board of directors approved a new share repurchase program with no expiration date pursuant to which the company may repurchase its ordinary shares for up to an aggregate purchase price of $500 million, exclusive of any brokerage commissions.

Additionally, in the third quarter, the company amended and extended the company's Term Loan B, reducing the applicable margin by 50 basis points and extending the maturity by five years to May 2033, which is expected to generate cash interest savings and maintain cash reserves.

Financial Highlights

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| (In millions, except per share amounts) | 2026 | | 2025 | | 2026 | | 2025 |

| Total revenues | $ 1,243.0 | | $ 1,126.1 | | $ 3,520.2 | | $ 3,069.6 |

| GAAP net income (loss) | $ (483.4) | | $ 251.4 | | $ 2.5 | | $ (559.6) |

| Non-GAAP adjusted net income (loss) | $ (250.8) | | $ 500.7 | | $ 565.1 | | $ 101.0 |

| GAAP earnings (loss) per share | $ (7.48) | | $ 4.08 | | $ 0.04 | | $ (9.18) |

| Non-GAAP adjusted earnings (loss) per share | $ (3.88) | | $ 8.13 | | $ 8.23 | | $ 1.63 |

GAAP net loss and non-GAAP adjusted net loss in 3Q26 included acquired in-process research and development (IPR&D) expense of $754 million representing the value allocated to ABS-1230 (JZP6979) in the Actio acquisition, which impacted our results by $11.32 per share and $11.03 per share on a GAAP and non-GAAP adjusted basis, respectively.

Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.

Total Revenues

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| (In millions) | 2026 | | 2025 | | 2026 | | 2025 |

| Xywav | $ 482.8 | | $ 431.4 | | $ 1,362.2 | | $ 1,191.5 |

| Xyrem | 31.2 | | 35.7 | | 92.9 | | 108.3 |

| Sleep | 514.0 | | 467.1 | | 1,455.1 | | 1,299.8 |

| Epidiolex/Epidyolex | 295.4 | | 302.6 | | 837.3 | | 772.0 |

| Epilepsy | 295.4 | | 302.6 | | 837.3 | | 772.0 |

| Zepzelca | 104.4 | | 79.3 | | 311.2 | | 216.8 |

| Rylaze/Enrylaze | 106.3 | | 99.9 | | 309.5 | | 294.8 |

| Defitelio/defibrotide | 60.7 | | 51.7 | | 170.1 | | 140.5 |

| Modeyso | 61.1 | | 11.0 | | 150.7 | | 11.5 |

| Vyxeos | 34.0 | | 37.6 | | 92.0 | | 112.0 |

| Ziihera | 20.6 | | 8.3 | | 49.3 | | 16.3 |

| Oncology | 387.1 | | 287.8 | | 1,082.8 | | 791.9 |

| Other | — | | 6.9 | | 2.7 | | 25.7 |

| Product sales, net | 1,196.5 | | 1,064.4 | | 3,377.9 | | 2,889.4 |

| High-sodium oxybate AG royalty revenue | 38.4 | | 52.9 | | 116.9 | | 155.9 |

| Other royalty and contract revenues | 8.1 | | 8.8 | | 25.4 | | 24.3 |

| Total revenues | $ 1,243.0 | | $ 1,126.1 | | $ 3,520.2 | | $ 3,069.6 |

Total revenues increased 10% YoY in 3Q26 primarily due to higher Xywav, Zepzelca and Ziihera net product sales and the inclusion of Modeyso net product sales, following FDA approval in August 2025.

Operating Expenses and Income Tax Expense (Benefit)

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| (In millions, except percentages) | 2026 | | 2025 | | 2026 | | 2025 |

| GAAP: | | | | | | | |

| Cost of product sales | $ 110.6 | | $ 128.9 | | $ 361.1 | | $ 349.8 |

| Gross margin on total revenues | 91.1 % | | 88.6 % | | 89.7 % | | 88.6 % |

| Selling, general and administrative | $ 407.9 | | $ 530.6 | | $ 1,149.8 | | $ 1,403.0 |

| % of total revenues | 32.8 % | | 47.1 % | | 32.7 % | | 45.7 % |

| Research and development | $ 211.9 | | $ 198.2 | | $ 615.4 | | $ 568.8 |

| % of total revenues | 17.0 % | | 17.6 % | | 17.5 % | | 18.5 % |

| Acquired in-process research and development | $ 754.2 | | $ 42.5 | | $ 831.2 | | $ 947.9 |

| Gain on sale of priority review voucher | $ — | | $ — | | $ (122.8) | | $ — |

| Income tax expense (benefit) | $ 24.5 | | $ (242.4) | | $ 48.7 | | $ (277.4) |

| Effective tax rate | (5.3) % | | N/A(1) | | 94.9 % | | 33.2 % |

| _________________________ |

| 1. | Not a meaningful metric due to minimal profit before tax in this period. |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| (In millions, except percentages) | 2026 | | 2025 | | 2026 | | 2025 |

| Non-GAAP adjusted: | | | | | | | |

| Cost of product sales | $ 105.1 | | $ 83.2 | | $ 290.2 | | $ 229.2 |

| Gross margin on total revenues | 91.5 % | | 92.6 % | | 91.8 % | | 92.5 % |

| Selling, general and administrative | $ 328.0 | | $ 460.1 | | $ 979.7 | | $ 1,242.7 |

| % of total revenues | 26.4 % | | 40.9 % | | 27.8 % | | 40.5 % |

| Research and development | $ 188.9 | | $ 169.9 | | $ 546.1 | | $ 496.7 |

| % of total revenues | 15.2 % | | 15.1 % | | 15.5 % | | 16.2 % |

| Acquired in-process research and development | $ 754.2 | | $ 42.5 | | $ 831.2 | | $ 947.9 |

| Income tax expense (benefit) | $ 72.1 | | $ (178.8) | | $ 187.7 | | $ (100.1) |

| Effective tax rate | (40.3) % | | (55.5) % | | 24.9 % | | N/A(1) |

| _________________________ |

| 1. | Not a meaningful metric due to minimal profit before tax in this period. |

Changes in operating expenses and income tax expense (benefit) in 3Q26 over the prior year period are primarily due to the following:

  • Cost of product sales, on a GAAP basis, decreased in 3Q26, primarily due to the full recognition of the inventory fair value step-up in the second quarter of 2026, partially offset by higher royalty expenses, driven by higher revenues of Modeyso and Zepzelca. Cost of product sales, on a non-GAAP adjusted basis, increased in 3Q26, primarily due to the higher royalty expenses.

  • Selling, general and administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, decreased in 3Q26, primarily due to litigation settlements of $152 million in 3Q25, partially offset, on a GAAP basis, by restructuring expenses of $34 million included in 3Q26.

  • Research and development (R&D) expenses, on a GAAP and non-GAAP adjusted basis, increased in 3Q26, reflecting continued investment in our pipeline portfolio and evidence generation.

  • Acquired IPR&D of $754 million, on a GAAP and non-GAAP adjusted basis, in 3Q26, represents the value allocated to ABS-1230 (JZP6979) in the Actio acquisition.

  • We recognized an income tax expense, on a GAAP and non-GAAP adjusted basis, in 3Q26 compared to an income tax benefit in 3Q25, which included a benefit of $206 million on recognition of certain U.S. federal and state deferred tax assets acquired through our acquisition of Chimerix.

Cash Flow and Balance SheetAs of September 30, 2026, cash, cash equivalents and investments were $2.9 billion, and the outstanding principal balance of the company's long-term debt was $5.6 billion. In addition, the company had undrawn borrowing capacity under a revolving credit facility of $885 million. For the nine months ended September 30, 2026, the company generated $1.3 billion of cash from operations reflecting strong business performance and continued financial discipline.

2026 Financial GuidanceJazz Pharmaceuticals has updated its full-year financial guidance, as shown in the table below, including raising its full-year 2026 revenue guidance, increasing its GAAP SG&A expense guidance to include restructuring expenses, and updating its effective tax rate guidance range to reflect the impact of the acquired IPR&D expense associated with the Actio acquisition.

| | Guidance provided as of |

| (In millions) | November 2, 2026 | | August 3, 2026 |

| Total Revenues | $4,775 - $4,850 | | $4,600 - $4,750 |

GAAP:

| (In millions, except percentages) | November 2, 2026 | | August 3, 2026 |

| Gross margin % | 89% - 90% | | 89% - 90% |

| SG&A expenses | $1,544 - $1,597 | | $1,506 - $1,556 |

| R&D expenses | $819 - $876 | | $818 - $873 |

| Effective tax rate | 20% - 30% | | 0% - 10% |

| Weighted-average diluted shares outstanding | 69 - 70 | | 69 - 70 |

Non-GAAP adjusted:

| (In millions, except percentages) | November 2, 2026 | | August 3, 2026 |

| Gross margin % | 90.5% - 91.5%1 | | 90% - 91% |

| SG&A expenses | $1,330 - $1,3701 | | $1,330 - $1,370 |

| R&D expenses | $725 - $7751 | | $725 - $775 |

| Effective tax rate | 19.5% - 21.5%1 | | 11.5% - 13.5% |

| Weighted-average diluted shares outstanding | 69 - 70 | | 69 - 70 |

| ___________________________ |

| 1. | See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included in the table titled "Reconciliation of 2026 GAAP to Non-GAAP Guidance Measures." |

Conference Call Details

Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. ET to provide a business and financial update and discuss its 2026 third quarter results.

Interested parties may register for the call here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this press release that exclude certain items that are included in the most directly comparable GAAP financial measures, as detailed in the accompanying tables. The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period, to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

Cautionary Note Concerning Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to: the company's growth prospects and future financial and operating results, including the company's 2026 financial guidance and the company's expectations related thereto, including with respect to anticipated catalysts; the company's advancement of pipeline programs and the timing of development activities, regulatory activities, approvals, and submissions related thereto; the prospective benefits of the company's acquisition of Actio and the potential of ABS-1230 (now JZP6979) for the treatment of KCNT1-related epilepsy; the company's expectations with respect to its regulatory submissions, including its NDA for a cannabidiol oral capsule formulation for potential use in existing approved Epidiolex/Epidyolex formulations and its NDA for JZP6979 in KCNT1-related epilepsy; and the company's development, regulatory and commercialization strategy, including the company's expectation of portfolio expansion through business development and its research and development engine; the company's expectations with respect to its products and product candidates and the potential of the company's products and product candidates and the potential regulatory path related thereto; the company's capital allocation and corporate development strategy; the commercial potential of the company's products; the company's views and expectations relating to its patent portfolio; and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Epidiolex/Epidyolex, Ziihera, Modeyso, Zepzelca and other lead marketed products; effectively launching and commercializing the company's other products and product candidates; the successful completion of development and regulatory activities with respect to the company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the company's products; the time-consuming and uncertain regulatory approval process; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; global economic, financial, and healthcare system disruptions; protecting and enhancing the company's intellectual property rights and the company's commercial success being dependent upon the company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the company's products and product candidates; the company's ability to realize the anticipated benefits from its acquisition of Actio; complying with applicable U.S. and non-U.S. regulatory requirements; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired products, product candidates and businesses; the company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the company's cash flows and capital resources; the company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the company's ability to meet its projected long-term goals and objectives, in the time periods that the company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the company's long-term goals and objectives; fluctuations in the market price and trading volume of the company's ordinary shares; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including the company's Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and future filings and reports by the company. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

| JAZZ PHARMACEUTICALS PLC |

| CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) |

| (In millions, except per share amounts) |

| (Unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Revenues: | | | | | | | |

| Product sales, net | $ 1,196.5 | | $ 1,064.4 | | $ 3,377.9 | | $ 2,889.4 |

| Royalties and contract revenues | 46.5 | | 61.7 | | 142.3 | | 180.2 |

| Total revenues | 1,243.0 | | 1,126.1 | | 3,520.2 | | 3,069.6 |

| Operating expenses: | | | | | | | |

| Cost of product sales (excluding amortization of acquired developed technologies) | 110.6 | | 128.9 | | 361.1 | | 349.8 |

| Selling, general and administrative | 407.9 | | 530.6 | | 1,149.8 | | 1,403.0 |

| Research and development | 211.9 | | 198.2 | | 615.4 | | 568.8 |

| Intangible asset amortization | 171.8 | | 168.4 | | 514.1 | | 484.9 |

| Acquired in-process research and development | 754.2 | | 42.5 | | 831.2 | | 947.9 |

| Gain on sale of priority review voucher | — | | — | | (122.8) | | — |

| Total operating expenses | 1,656.4 | | 1,068.6 | | 3,348.8 | | 3,754.4 |

| Income (loss) from operations | (413.4) | | 57.5 | | 171.4 | | (684.8) |

| Interest expense, net | (45.5) | | (48.6) | | (122.5) | | (149.7) |

| Foreign exchange gain (loss) | — | | 0.1 | | 2.4 | | (1.9) |

| Income (loss) before income tax expense (benefit) and equity in loss of investees | (458.9) | | 9.0 | | 51.3 | | (836.4) |

| Income tax expense (benefit) | 24.5 | | (242.4) | | 48.7 | | (277.4) |

| Equity in loss of investees | — | | — | | 0.1 | | 0.6 |

| Net income (loss) | $ (483.4) | | $ 251.4 | | $ 2.5 | | $ (559.6) |

| | | | | | | | |

| Net income (loss) per ordinary share: | | | | | | | |

| Basic | $ (7.48) | | $ 4.14 | | $ 0.04 | | $ (9.18) |

| Diluted | $ (7.48) | | $ 4.08 | | $ 0.04 | | $ (9.18) |

| Weighted-average ordinary shares used in per share calculations - basic | 64.7 | | 60.7 | | 63.3 | | 61.0 |

| Weighted-average ordinary shares used in per share calculations - diluted | 64.7 | | 61.6 | | 68.6 | | 61.0 |

| JAZZ PHARMACEUTICALS PLC |

| CONDENSED CONSOLIDATED BALANCE SHEETS |

| (In millions) |

| (Unaudited) |

| |

| | September 30, 2026 | | December 31, 2025 |

| ASSETS | | | |

| Current assets: | | | |

| Cash and cash equivalents | $ 2,036.4 | | $ 1,391.9 |

| Investments | 820.0 | | 1,050.0 |

| Accounts receivable, net of allowances | 873.7 | | 830.7 |

| Inventories | 454.0 | | 417.0 |

| Prepaid expenses | 170.9 | | 152.5 |

| Other current assets | 258.4 | | 323.9 |

| Total current assets | 4,613.4 | | 4,166.0 |

| Property, plant and equipment, net | 224.8 | | 199.9 |

| Operating lease assets | 67.2 | | 58.9 |

| Intangible assets, net | 4,173.7 | | 4,429.5 |

| Goodwill | 1,802.8 | | 1,829.3 |

| Deferred tax assets, net | 998.7 | | 869.1 |

| Deferred financing costs | 6.1 | | 7.6 |

| Other non-current assets | 111.0 | | 99.0 |

| Total assets | $ 11,997.7 | | $ 11,659.3 |

| LIABILITIES AND SHAREHOLDERS' EQUITY | | | |

| Current liabilities: | | | |

| Accounts payable | $ 380.3 | | $ 122.1 |

| Accrued liabilities | 1,076.4 | | 1,034.2 |

| Current portion of long-term debt | 1,017.3 | | 1,029.9 |

| Income taxes payable | 59.2 | | 56.3 |

| Total current liabilities | 2,533.2 | | 2,242.5 |

| Long-term debt, less current portion | 4,552.1 | | 4,328.4 |

| Operating lease liabilities, less current portion | 60.7 | | 50.9 |

| Deferred tax liabilities, net | 506.1 | | 594.5 |

| Other non-current liabilities | 153.8 | | 124.4 |

| Total shareholders' equity | 4,191.8 | | 4,318.6 |

| Total liabilities and shareholders' equity | $ 11,997.7 | | $ 11,659.3 |

| JAZZ PHARMACEUTICALS PLC |

| SUMMARY OF CASH FLOWS |

| (In millions) |

| (Unaudited) |

| |

| | Nine Months Ended September 30, |

| | 2026 | | 2025 |

| Net cash provided by operating activities | $ 1,330.0 | | $ 993.3 |

| Net cash used in investing activities | (605.8) | | (1,137.8) |

| Net cash used in financing activities | (79.3) | | (948.8) |

| Effect of exchange rates on cash and cash equivalents | (0.4) | | 6.5 |

| Net increase (decrease) in cash and cash equivalents | $ 644.5 | | $ (1,086.8) |

| JAZZ PHARMACEUTICALS PLC |

| RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION |

| (In millions, except per share amounts) |

| (Unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| | Net Loss | | Diluted Loss Per Share (LPS) | | Net Income | | Diluted Earnings Per Share (EPS) | | Net Income | | Diluted EPS | | Net Income (Loss) | | Diluted EPS / (LPS) |

| GAAP reported | $ (483.4) | | $ (7.48) | | $ 251.4 | | $ 4.08 | | $ 2.5 | | $ 0.04 | | $ (559.6) | | $ (9.18) |

| Intangible asset amortization | 171.8 | | 2.66 | | 168.4 | | 2.73 | | 514.1 | | 7.49 | | 484.9 | | 7.83 |

| Share-based compensation expense | 73.8 | | 1.14 | | 88.1 | | 1.43 | | 221.6 | | 3.23 | | 220.3 | | 3.56 |

| Acquisition accounting inventory fair value step-up | — | | — | | 40.4 | | 0.66 | | 54.1 | | 0.79 | | 107.3 | | 1.73 |

| Restructuring and other costs | 34.2 | | 0.53 | | — | | — | | 34.2 | | 0.50 | | — | | — |

| Gain on sale of PRV | — | | — | | — | | — | | (122.8) | | (1.79) | | — | | — |

| Integration related expenses1 | 0.4 | | 0.01 | | 16.0 | | 0.26 | | 0.4 | | 0.01 | | 25.4 | | 0.41 |

| Income tax effect of above adjustments | (47.6) | | (0.74) | | (63.6) | | (1.03) | | (139.0) | | (2.04) | | (177.3) | | (2.86) |

| Effect of potentially dilutive ordinary shares on non-GAAP adjusted EPS | — | | — | | — | | — | | — | | — | | — | | 0.14 |

| Non-GAAP adjusted | $ (250.8) | | $ (3.88) | | $ 500.7 | | $ 8.13 | | $ 565.1 | | $ 8.23 | | $ 101.0 | | $ 1.63 |

| | | | | | | | | | | | | | | | |

| Weighted-average ordinary shares used in diluted per share calculations - GAAP | 64.7 | | | | 61.6 | | | | 68.6 | | | | 61.0 | | |

| Dilutive effect of employee equity incentive and purchase plans | — | | | | — | | | | — | | | | 0.9 | | |

| Weighted-average ordinary shares used in diluted per share calculations - GAAP and non-GAAP | 64.7 | | | | 61.6 | | | | 68.6 | | | | 61.9 | | |

| ________________________________________________ |

| 1. | Integration related expenses with respect to the Actio acquisition and the Chimerix acquisition. |

| |

| |

| JAZZ PHARMACEUTICALS PLC |

| RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION - CERTAIN LINE ITEMS |

| (In millions, except percentages) |

| (Unaudited) |

| |

| | Three months ended September 30, 2026 |

| | Cost of product sales | | Gross margin | | SG&A | | R&D | | Intangible asset amortization | | Acquired IPR&D | | Interest expense, net | | Income tax expense | | Effective tax rate |

| GAAP Reported | $ 110.6 | | 91.1 % | | $ 407.9 | | $ 211.9 | | $ 171.8 | | $ 754.2 | | $ 45.5 | | $ 24.5 | | (5.3) % |

| Non-GAAP Adjustments: | | | | | | | | | | | | | | | | | |

| Intangible asset amortization | — | | — | | — | | — | | (171.8) | | — | | — | | — | | — |

| Share-based compensation expense | (5.5) | | 0.4 | | (45.4) | | (22.9) | | — | | — | | — | | — | | — |

| Restructuring and other costs | — | | — | | (34.2) | | — | | — | | — | | — | | — | | — |

| Integration related expenses | — | | — | | (0.3) | | (0.1) | | — | | — | | — | | — | | — |

| Income tax effect of above adjustments | — | | — | | — | | — | | — | | — | | — | | 47.6 | | (35.0) |

| Total of non-GAAP adjustments | (5.5) | | 0.4 | | (79.9) | | (23.0) | | (171.8) | | — | | — | | 47.6 | | (35.0) |

| Non-GAAP Adjusted | $ 105.1 | | 91.5 % | | $ 328.0 | | $ 188.9 | | $ — | | $ 754.2 | | $ 45.5 | | $ 72.1 | | (40.3) % |

| | |

| | Three months ended September 30, 2025 |

| | Cost of product sales | | Gross margin | | SG&A | | R&D | | Intangible asset amortization | | Acquired IPR&D | | Interest expense, net | | Income tax benefit | | Effective tax rate |

| GAAP Reported | $ 128.9 | | 88.6 % | | $ 530.6 | | $ 198.2 | | $ 168.4 | | $ 42.5 | | $ 48.6 | | $ (242.4) | | N/A(1) |

| Non-GAAP Adjustments: | | | | | | | | | | | | | | | | | |

| Intangible asset amortization | — | | — | | — | | — | | (168.4) | | — | | — | | — | | — |

| Share-based compensation expense | (5.0) | | 0.4 | | (61.3) | | (21.8) | | — | | — | | — | | — | | — |

| Integration related expenses | (0.3) | | — | | (9.2) | | (6.5) | | — | | — | | — | | — | | — |

| Acquisition accounting inventory fair value step-up | (40.4) | | 3.6 | | — | | — | | — | | — | | — | | — | | — |

| Income tax effect of above adjustments | — | | — | | — | | — | | — | | — | | — | | 63.6 | | N/A(1) |

| Total of non-GAAP adjustments | (45.7) | | 4.0 | | (70.5) | | (28.3) | | (168.4) | | — | | — | | 63.6 | | N/A(1) |

| Non-GAAP Adjusted | $ 83.2 | | 92.6 % | | $ 460.1 | | $ 169.9 | | $ — | | $ 42.5 | | $ 48.6 | | $ (178.8) | | (55.5) % |

| _________________________ |

| 1. | Not a meaningful metric due to minimal GAAP profit before tax in this period. |

| JAZZ PHARMACEUTICALS PLC | | |

| RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION - CERTAIN LINE ITEMS | | |

| (In millions, except percentages) | | |

| (Unaudited) | | |

| | | |

| | Nine months ended September 30, 2026 | | |

| | Cost of product sales | | Gross margin | | SG&A | | R&D | | Intangible asset amortization | | Gain on sale of PRV | | Acquired IPR&D | | Interest expense, net | | Income tax expense | | Effective tax rate |

| GAAP Reported | $ 361.1 | | 89.7 % | | $ 1,149.8 | | $ 615.4 | | $ 514.1 | | $ (122.8) | | $ 831.2 | | $ 122.5 | | $ 48.7 | | 94.9 % |

| Non-GAAP Adjustments: | | | | | | | | | | | | | | | | | | | |

| Intangible asset amortization | — | | — | | — | | — | | (514.1) | | — | | — | | — | | — | | — |

| Share-based compensation expense | (16.8) | | 0.5 | | (135.6) | | (69.2) | | — | | — | | — | | — | | — | | — |

| Acquisition accounting inventory fair value step-up | (54.1) | | 1.6 | | — | | — | | — | | — | | — | | — | | — | | — |

| Restructuring and other costs | — | | — | | (34.2) | | — | | — | | | | — | | — | | — | | — |

| Integration related expenses | — | | — | | (0.3) | | (0.1) | | — | | — | | — | | — | | — | | — |

| Gain on sale of PRV | — | | — | | — | | — | | — | | 122.8 | | — | | — | | — | | — |

| Income tax effect of above adjustments | — | | — | | — | | — | | — | | — | | — | | — | | 139.0 | | (70.0) |

| Total of non-GAAP adjustments | (70.9) | | 2.1 | | (170.1) | | (69.3) | | (514.1) | | 122.8 | | — | | — | | 139.0 | | (70.0) |

| Non-GAAP Adjusted | $ 290.2 | | 91.8 % | | $ 979.7 | | $ 546.1 | | $ — | | $ — | | $ 831.2 | | $ 122.5 | | $ 187.7 | | 24.9 % |

| | |

| | Nine months ended September 30, 2025 |

| | Cost of product sales | | Gross margin | | SG&A | | R&D | | Intangible asset amortization | | Acquired IPR&D | | Interest expense, net | | Income tax benefit | | Effective tax rate |

| GAAP Reported | $ 349.8 | | 88.6 % | | $ 1,403.0 | | $ 568.8 | | $ 484.9 | | $ 947.9 | | $ 149.7 | | $ (277.4) | | 33.2 % |

| Non-GAAP Adjustments: | | | | | | | | | | | | | | | | | |

| Intangible asset amortization | — | | — | | — | | — | | (484.9) | | — | | — | | — | | — |

| Share-based compensation expense | (13.0) | | 0.4 | | (144.0) | | (63.3) | | — | | — | | — | | — | | — |

| Integration related expenses | (0.3) | | — | | (16.3) | | (8.8) | | — | | — | | — | | — | | — |

| Acquisition accounting inventory fair value step-up | (107.3) | | 3.5 | | — | | — | | — | | — | | — | | — | | — |

| Income tax effect of above adjustments | — | | — | | — | | — | | — | | — | | — | | 177.3 | | N/A(1) |

| Total of non-GAAP adjustments | (120.6) | | 3.9 | | (160.3) | | (72.1) | | (484.9) | | — | | — | | 177.3 | | N/A(1) |

| Non-GAAP Adjusted | $ 229.2 | | 92.5 % | | $ 1,242.7 | | $ 496.7 | | $ — | | $ 947.9 | | $ 149.7 | | $ (100.1) | | N/A(1) |

| _________________________ |

| 1. | Not a meaningful metric due to minimal non-GAAP profit before tax in this period. |

| JAZZ PHARMACEUTICALS PLC |

| RECONCILIATION OF 2026 GAAP TO NON-GAAP GUIDANCE MEASURES |

| |

| | Projected Range |

| (In millions, except percentages) | Low | | High |

| GAAP gross margin on total revenues | 89 % | | 90 % |

| Acquisition accounting inventory fair value step-up | 1 % | | 1 % |

| Share-based compensation expense | 0.5 % | | 0.5 % |

| Non-GAAP gross margin on total revenues | 90.5 % | | 91.5 % |

| | | | |

| GAAP SG&A expenses | $ 1,544 | | $ 1,597 |

| Share-based compensation expense | (176) | | (186) |

| Restructuring and other costs | (34) | | (34) |

| Integration related expenses | (4) | | (7) |

| Non-GAAP SG&A expenses | $ 1,330 | | $ 1,370 |

| | | | |

| GAAP R&D expenses | $ 819 | | $ 876 |

| Share-based compensation expense | (93) | | (98) |

| Integration related expenses | (1) | | (3) |

| Non-GAAP R&D expenses | $ 725 | | $ 775 |

| | | | |

| GAAP effective tax rate | 20 % | | 30 % |

| Income tax effect of GAAP to non-GAAP reconciling items | (0.5) % | | (8.5) % |

| Non-GAAP effective tax rate | 19.5 % | | 21.5 % |

Prompts

Jazz Pharmaceuticals plc (ticker JAZZ), listed in United States.

Company History

Date Change Detail
May 10, 2016 Acquired Acquired Celator Pharmaceuticals Inc (CIK 1327467). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Jazz Pharmaceuticals plc

ETF Weight in ETF Shares Market value As of
PINK 3.70% 51,406 $ 12.374M Nov 17, 2026
QMOM 2.30% 36,424 $ 8.77M Nov 18, 2026
ABIG 2.21% 5,465 $ 1.32M Nov 18, 2026
SMRI 2.00% 57,774 $ 13.91M Nov 18, 2026
AMID 1.69% 8,143 $ 1.96M Nov 18, 2026
KNO 1.68% 3,160 $ 761.465K Jun 30, 2026
SHRT 1.60% 863 $ 206.922K Nov 17, 2026
TAX 1.44% 1,458 $ 365.491K Aug 31, 2026
HWSM 1.16% 133 $ 32.049K Jun 30, 2026
DSMC 1.01% 5,399 $ 1.301M Jun 30, 2026
SEIV 0.90% 54,952 $ 13.242M Jun 30, 2026
FFOG 0.82% 10,574 $ 2.548M Jun 30, 2026
CLSE 0.80% 28,810 $ 7.222M Aug 31, 2026
HELX 0.78% 905 $ 218.078K Jun 30, 2026
MCDS 0.74% 243 $ 58.493K Nov 17, 2026
LVDS 0.62% 3,075 $ 740.183K Nov 17, 2026
LSVD 0.58% 14,802 $ 3.743M Jul 31, 2026
BKDV 0.55% 39,844 $ 10.075M Jul 31, 2026
EHLS 0.54% 1,207 $ 289.402K Nov 17, 2026
AVMV 0.50% 17,409 $ 4.174M Nov 16, 2026
ABCS 0.49% 245 $ 61.417K Aug 31, 2026
WCEO 0.48% 188 $ 47.538K Jul 31, 2026
ITAN 0.47% 2,418 $ 582.037K Nov 17, 2026
JMEE 0.46% 54,586 $ 13.139M Nov 17, 2026
AFMC 0.41% 4,538 $ 1.088M Nov 16, 2026
SIXL 0.40% 3,503 $ 842.016K Nov 12, 2026
DSTL 0.36% 31,981 $ 7.706M Jun 30, 2026
DFAT 0.30% 390,162 $ 93.783M Nov 12, 2026
SMDX 0.29% 1,533 $ 367.567K Nov 17, 2026
AVLV 0.28% 265,468 $ 63.651M Nov 16, 2026
VFMO 0.27% 20,891 $ 5.237M Aug 31, 2026
VFMF 0.26% 10,247 $ 2.569M Aug 31, 2026
GVLU 0.23% 2,458 $ 589.355K Nov 17, 2026
AVMC 0.20% 4,574 $ 1.097M Nov 16, 2026
DFAS 0.18% 253,049 $ 60.825M Nov 12, 2026
TMSL 0.17% 19,155 $ 4.616M Jun 30, 2026
AVUQ 0.17% 2,964 $ 710.678K Nov 16, 2026
VFVA 0.17% 6,366 $ 1.596M Aug 31, 2026
FTLS 0.16% 17,335 $ 0.00 Nov 16, 2026
EBI 0.14% 3,779 $ 947.32K Aug 31, 2026
AVSU 0.13% 2,586 $ 620.045K Nov 16, 2026
AVIE 0.12% 83 $ 19.901K Nov 16, 2026
AVLC 0.09% 5,868 $ 1.407M Nov 16, 2026
AVUS 0.08% 47,217 $ 11.321M Nov 16, 2026
DFUV 0.07% 47,343 $ 11.38M Nov 12, 2026
DFAC 0.07% 241,507 $ 58.051M Nov 12, 2026
VSLU 0.05% 1,193 $ 287.477K Jun 30, 2026
DFSU 0.05% 5,057 $ 1.216M Nov 12, 2026
MSSM 0.05% 1,393 $ 349.197K Aug 31, 2026
DCOR 0.05% 89,836 $ 21.594M Nov 12, 2026
DFAU 0.03% 18,647 $ 4.482M Nov 12, 2026
DXUV 0.02% 6,354 $ 1.527M Nov 12, 2026
DFUS 0.02% 20,528 $ 4.934M Nov 12, 2026
IALT 0.02% 7,155 $ 1.716M Nov 16, 2026
MSLC 0.00% 777 $ 194.778K Aug 31, 2026
DYNF 0.00% 36 $ 8,631.72 Nov 16, 2026